Medicines Optimisation Centricity – Getting It Right

Medicines Optimisation Centricity – Getting It Right

Petersfield, Hampshire, October 2023, Aspire Pharma Ltd initiated and funded the set-up of a series of round table events to discuss Medicines Optimisation Centricity. These events, facilitated by Wilmington Healthcare, as a data intelligence agency, brought together a number of NHS thought leaders from a wide range of disciplines, and led to the creation of a White Paper on medicines optimisation.

The White Paper focuses on the NHS’ approach to providing engagement, choice, and access to medicines in a timely manner. There is a need for the NHS and pharmaceutical businesses to work collaboratively to ensure a patient centric approach is established, with a shared understanding of individual patients. With the right resources, tools, and knowledge, we can help lift barriers in patient care.

Medicines optimisation looks at the value medicines deliver; that they are both clinically and cost effective. Ensuring patients get the correct medicine, and dose, for the correct indication1, is not always easy. Effective medicines optimisation requires a collaborative approach by those responsible for delivering healthcare to the patient, including the patient themselves1.

Aspire has long sought to identify opportunities which bring innovative solutions for the benefit of patients, using their expertise to develop strong partnerships with payors, providers, and healthcare professionals.

Together, these partnerships can help deliver a breadth and depth of knowledge to assist in customer and patient centricity, that meets the unmet needs of every patient; thus, making a difference in the lives of patients­­­­ through the development and supply of innovative products and medicines throughout the world.

Richard Condon, CEO at Aspire said: “I would like to congratulate our partners involved in the Medicines Optimisation Centricity Project, which is an excellent example of where we have identified a problem, become co-partners, and worked collaboratively at the highest levels to find a solution.

“This project puts patient care at the top of the agenda and will help lead to better access, value and choice for the NHS.”

The Meds Ops Centricity – It’s Time to Optimise Medicines Optimisation White Paper can be found at: https://www.hsj.co.uk/integrated-care/its-time-to-optimise-medicines-optimisation/7034815.article#.ZG98K1eQAU4.linkedin.

Here is a direct link to the White Paper: https://meds-ops-centricity.co.uk/

Aspire Pharma initiated and funded the set-up of a series of round table events to discuss Medicines Optimisation Centricity. This led to the creation of a White Paper on medicines optimisation. Aspire had no input into the content of the White Paper and reviewed it for factual accuracy and compliance checks only.

References

  1. https://www.england.nhs.uk/medicines-2/medicines-optimisation/

10104511986 v 2.0 October 2023                                                          

Aspire Pharma Continues LCCC’s Medical Centre Sponsorship

Aspire Pharma Continues LCCC’s Medical Centre Sponsorship

Leicestershire County Cricket Club (LCCC) is delighted to announce Aspire Pharma Ltd as the new sponsor of the club’s state-of-the-art medical centre at the Uptonsteel Ground, at Grace Road.

Since 2016, the medical centre has been sponsored by Loughborough-based Morningside Pharmaceuticals, which was acquired by Aspire in 2022. This acquisition will create a leading fast-growing, top-30 UK specialty pharma company.

The newly named Aspire Medical Centre will continue to be a critical treatment area for the club’s players; where specialist physio can be carried out, as well as urgent medical assistance provided in an emergency.

As the medical centre has become more established, it has developed into a hub for sports science and medicine. Hundreds of junior cricketers from LCCC’s Academy are invited to visit and learn more about these key study areas each year.

Richard Condon, Chief Executive of Aspire Pharma, said: “At Aspire, our mission is to make a difference to the lives of patients through the development and supply of innovative products and medicines throughout the world, which this partnership very much aligns with.  

“We’re proud to continue our support of the Aspire Medical Centre, which has developed into an essential treatment facility for the club. It has also become an education hub for the benefit of the players, public and wider community.”  

Prior to the creation of the Aspire Medical Centre in 2016, the club had to treat players and visitors off-site, which was not ideal if a member of the public or player became seriously ill.

Sean Jarvis CEO of LCCC, said: “We’re delighted to welcome Aspire Pharma as the medical centre’s new sponsor. It’s great news that Aspire will be continuing our partnership, which has made such a huge difference to the sports science, physiotherapy, and medical treatment facilities at Grace Road.”

The medical centre, in the Lower Meet, provides Leicestershire County Cricket Club players with state-of-the-art match preparation and rehabilitation support from injuries. It has a space for a private treatment room, an open plan treatment area and an adjoining trauma room, which doubles as a crowd medical facility for use by St John’s Ambulance on match days.

Ryan Smith, Head of Sports Science and Medicine at the club, said: “The cricket season is demanding and can take its toll on the players’ bodies. For the team to reach the highest level it’s essential that we have the best facilities onsite to treat and rehabilitate the players. This access allows our teams to deliver individualised treatments at any time and enables our players to consistently train all year round.

“The medical centre’s facilities are an important part of our pre-match, during and post-match physiotherapy and sports science infrastructure. It has enabled us to progress the rehabilitation of our injured athletes by increasing the access we have to a usable and functional training environment.

“This will hopefully give our players the winning edge in the different championships they are competing in this cricket season.”    

Aspire Pharma acquires Morningside Pharmaceuticals and Morningside Healthcare and its subsidiaries, including Morningside Healthcare (India) creating the UK’s premier Speciality Pharma company

Aspire Pharma acquires Morningside Pharmaceuticals and Morningside Healthcare and its subsidiaries, including Morningside Healthcare (India) creating the UK’s premier Speciality Pharma company

 

Petersfield, Hampshire, October 3rd 2022, Aspire Pharma Limited, today announced the successful completion of its acquisition of Morningside Pharmaceuticals (Loughborough), Morningside Healthcare (Leicester) and Morningside Healthcare (India) (together referred to as “Morningside”); privately owned, speciality generic pharmaceutical organisations.

Morningside delivers Aspire added talent, increased in-market range, and an industry leading pipeline, complementary to Aspire’s. The acquisition establishes Aspire as the premier Speciality Pharma organisation in the UK, with new opportunities to support international growth ambitions.

“We are excited to welcome the Morningside team to the Aspire family. This is a transformative opportunity for both companies to expand and enhance our position as a result of both companies highly complementary product portfolios. The combination will create one of the largest and fastest growing UK pharma companies and see further accelerated growth potential in our current and future product portfolio, in the UK and internationally. Our commitment remains with our team, patients, and our partners in the NHS and beyond, to ensure a smooth integration of businesses” said Richard Condon, Chief Executive Officer of Aspire Pharma.

“Aspire’s acquisition of Morningside is validation of the long-term growth plan that the shareholders and management of Morningside Pharmaceuticals and Morningside Healthcare have developed over the past 30 years. The combined company will benefit across several areas, including the realisation of enhanced business development capabilities with over 120 complementary mid and late-stage programs” said Tim Brady, Chief Executive Officer, Morningside.

Respective organisations will continue to operate as standalone businesses until further integration and transition announcements are made.

Additional Transaction Details

No terms of the financial agreement were disclosed by either party.

 

About Aspire Pharma

Aspire is present in the generics, speciality generics, branded medicines, and medical device sectors. Aspire’s investors include founder Graham Fraser-Pye; Juno Pharmaceuticals, a global pharma specialist organisation spanning four continents, focussing on niche differentiated products and H.I.G. Capital, a leading global alternative investment firm with over $50 billion* of equity capital under management. Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, and Atlanta in the USA, as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro and São Paulo.

 

About Morningside 

Morningside is a provider of licensed prescription medicines to the NHS and retail pharmacy sector, as well as international export markets. The business has over 300 Marketing Authorisations in the UK and Globally, covering a number of key therapeutic areas.

 

Disclosure Notice

The information contained in this release is as of October 3rd, 2022. Aspire assumes no obligation to update forward‐looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Aspire’s acquisition of Morningside Pharmaceuticals and Morningside Healthcare that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the ability to realise the anticipated benefits of the acquisition, including the possibility that the expected benefits from the acquisition will not be realised; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavourable new clinical data and further analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; whether and when license applications may be filed in any jurisdictions; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, the product(s) will be commercially successful.

*Based on total capital commitments managed by H.I.G. Capital and affiliates.

Global Licensing rights builds Aspire’s strategic commitment to develop therapies in the prevention of bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP) in preterm infants

Aspire Pharma Ltd, (Petersfield Hampshire), today announced the successful completion of its global licensing agreement of Retinolx , owned by Orphanix GmbH, a privately held, clinical-stage biopharmaceutical company focussed on the development of novel therapeutic orphan drugs across a range of paediatric therapy areas.

Retinolx brings Aspire a promising therapeutic candidate in BPD and ROP based on retinol (Vitamin A) allowing the option for both intramuscular and intravesical administration, specifically developed for preterm infants in the neonatal intensive care unit.

Orphanix have an approved EU PIP (paediatric investigation plan) and Orphan Designations for the Product in the European Union and in the United States of America in the indication ‘Prevention of bronchopulmonary dysplasia’ and ‘Prevention of retinopathy of prematurity’.

“We are excited to bring Orphanix’s promising investigational preventative treatment for BPD and ROP into our paediatric pipeline at Aspire. This acquisition demonstrates our commitment to advance the science and treatment options for Orphan Drug Designations in vulnerable patient groups. Through our in-house expertise and network of global leaders in these respective fields, we strive to bring breakthrough advances in clinical management” said Richard Condon, Chief Executive Officer of Aspire Pharma.

“Aspire’s investment in Retinolx demonstrates the belief that the Orphanix Management Team, and Board, have held for several years regarding the prevention of BPD and ROP. We look forward to bringing our category expertise to Aspire’s development and commercialisation capability to accelerate the development of this important treatment” said Dr. Philipp Heinrich Novak, Managing Director & Founder of Orphanix GmbH.

Additional Transaction Details

No terms of the financial agreement were disclosed by either party.

About Aspire Pharma

Aspire was established with a simple mission: To make a difference to the lives of patients through development and supply of innovative products and medicines that offer value to our customers.

Aspire is present in the generics, niche generics, branded medicines and medical device sectors. Aspire was majority acquired by H.I.G Capital ‘H.I.G’ in 2021. H.I.G. is a leading global alternative assets investment firm with over $50 billion of equity capital under management. Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, and Atlanta in the USA, as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro and São Paulo. For more information, go to www.aspirepharma.co.uk

About Orphanix GmbH

The Orphanix GmbH mission is to improve the lives of new-borns with rare diseases by filling blind spots with safe, innovative and readily accessible medical solutions. We are dedicated to fundamentally understand the needs of affected babies and to facilitate innovative opportunities for treatments.

We identify, develop and commercialize innovative orphan drugs across all paediatric indications based on in-depth evaluation of academic and real-world data.

Disclosure Notice

The information contained in this release is as of August 15, 2022. Aspire assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Aspire’s global licensing agreement of Retinolx, Orphanix’s development candidate in BPD and ROP that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the ability to realise the anticipated benefits of the global licensing agreement, including the possibility that the expected benefits from the global licensing agreement will not be realised; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavourable new clinical data and further analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; whether and when license applications may be filed in any jurisdictions; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, the product(s) will be commercially successful.

Media Contact

Email: [email protected] Tel: +44 1730 231148

Aspire welcome its new Chief Executive Officer:

It’s with great pleasure that Aspire officially welcome our new CEO, Richard Condon, to the company. Richard joins us from Bayer UK and as we embark on the next chapter, his leadership, knowledge, and experience, is a welcome addition to the team at a time we say a big thank you to the driving force behind Aspire Pharma, its founder, Graham Fraser-Pye. Graham’s vision for the company and the subsequent dedication and hard work to make it happen, saw us arrive at this point, and as he transitions into the new role of Chairman of the Aspire board, the company is positioned to build on these foundations and accelerate again. Richard commented;

“It is an honour and a privilege to be asked to lead such a rapidly growing and important business with an agenda for growth, and a talented and focussed team to deliver it. I am excited about my new role as CEO, and strongly believe in our mission – be agile to opportunity, unconstrained by market segment, with products that make a valuable difference to patients and payors.  I am thrilled to be part of writing the next chapter in our organisations story, and look forward to being part of, and learning from, such an amazing team. Exciting times!”

EPIMAX® sees an award-winning start to 2022

EPIMAX® sees an award-winning start to 2022

Aspire is delighted to announce the award-winning start to 2022 for its emollient range: EPIMAX®.

EPIMAX® Oatmeal Cream was selected as a highly commended product in the Best Beauty on a Budget category at the ASOS Beauty Awards 2022.

Beauty Magazine commented:

“This moisturiser provides light hydration and protection for sensitive skin without breaking the bank. Colloidal oatmeal helps to soothe dry skin, eczema and psoriasis symptoms triggered by allergens in the environment and moisturises skin to protect against irritants. It can be used as a moisturiser by smoothing into the skin in the direction of hair growth, or as a body wash in the shower to leave the skin feeling soft and comfortable.”

The awards don’t stop there, EPIMAX® was excited to be awarded highly commended for its EPIMAX® Oatmeal Cream at the MVP (Most Valuable Product) Awards.

Aspire welcome its new Chief Executive Officer: 5th April 2022

It’s with great pleasure that Aspire officially welcome our new CEO, Richard Condon, to the company. Richard joins us from Bayer UK and as we embark on the next chapter, his leadership, knowledge, and experience, is a welcome addition to the team at a time we say a big thank you to the driving force behind Aspire Pharma, its founder, Graham Fraser-Pye. Graham’s vision for the company and the subsequent dedication and hard work to make it happen, saw us arrive at this point, and as he transitions into the new role of Chairman of the Aspire board, the company is positioned to build on these foundations and accelerate again. Richard commented;

“It is an honour and a privilege to be asked to lead such a rapidly growing and important business with an agenda for growth, and a talented and focussed team to deliver it. I am excited about my new role as CEO, and strongly believe in our mission – be agile to opportunity, unconstrained by market segment, with products that make a valuable difference to patients and payors.  I am thrilled to be part of writing the next chapter in our organisations story, and look forward to being part of, and learning from, such an amazing team. Exciting times!”